PriceTargets.com logo

Roche - RHHVF Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$326.74 As of 02/14/2025 04:14 PM ET
▼ -3.258 (-0.99%)

This chart shows the closing price for RHHVF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Roche Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RHHVF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RHHVF

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Roche in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $326.74.

This chart shows the closing price for RHHVF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Roche. This rating has held steady since December 2023, when it changed from a Sell consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
8/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/22/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/22/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/18/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/17/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/16/2025

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/3/2023JPMorgan Chase & Co.DowngradeSell$275.00
2/28/2022Stifel NicolausInitiated CoverageBuy$410.00
12/22/2021CitigroupInitiated CoverageBuy$422.00
12/16/2021The Goldman Sachs GroupReiterated RatingBuy
11/24/2021Deutsche Bank AktiengesellschaftReiterated RatingBuy
9/17/2021JPMorgan Chase & Co.Reiterated RatingHold
9/15/2021Deutsche Bank AktiengesellschaftReiterated RatingBuy
9/7/2021Jefferies Financial GroupReiterated RatingBuy
8/10/2021Sanford C. BernsteinReiterated RatingBuy
8/10/2021Jefferies Financial GroupReiterated RatingBuy
7/5/2021JPMorgan Chase & Co.Reiterated RatingHold
6/25/2021The Goldman Sachs GroupReiterated RatingBuy
6/11/2021The Goldman Sachs GroupReiterated RatingBuy
4/21/2021BarclaysReiterated RatingBuy
4/21/2021Sanford C. BernsteinReiterated RatingBuy
4/19/2021JPMorgan Chase & Co.Reiterated RatingHold
3/23/2021UBS GroupReiterated RatingHold
3/23/2021JPMorgan Chase & Co.Reiterated RatingHold
2/10/2021JPMorgan Chase & Co.Reiterated RatingHold
2/7/2021Deutsche Bank AktiengesellschaftReiterated RatingHold
1/8/2021Berenberg BankReiterated RatingHold ➝ Neutral
12/11/2020Jefferies Financial GroupReiterated RatingBuy
12/7/2020JPMorgan Chase & Co.Reiterated RatingBuy
9/30/2020Berenberg BankReiterated RatingHold
9/2/2020UBS GroupReiterated RatingBuy
8/10/2020Sanford C. BernsteinReiterated RatingBuy
7/29/2020Credit Suisse GroupReiterated RatingHold
7/13/2020The Goldman Sachs GroupReiterated RatingBuy
6/25/2020Credit Suisse GroupReiterated RatingHold
6/25/2020JPMorgan Chase & Co.Reiterated RatingBuy
6/18/2020The Goldman Sachs GroupReiterated RatingBuy
5/14/2020JPMorgan Chase & Co.Reiterated RatingBuy
4/30/2020HSBCUpgradeHold
4/23/2020Credit Suisse GroupReiterated RatingHold
4/15/2020Jefferies Financial GroupReiterated RatingBuy
4/7/2020Deutsche Bank AktiengesellschaftReiterated RatingBuy
4/1/2020Redburn PartnersUpgradeBuy
2/17/2020CitigroupUpgradeBuy
(Data available from 2/16/2020 forward)

News Sentiment Rating

-0.04 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/21/2024
  • 0 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/20/2024
  • 1 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/19/2024
  • 0 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
10/19/2024
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/18/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/18/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/17/2025
  • 0 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
2/16/2025

Current Sentiment

  • 0 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Roche logo
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.
Read More

Today's Range

Now: $326.74
Low: $325.82
High: $330.15

50 Day Range

MA: $295.62
Low: $273.10
High: $330.00

52 Week Range

Now: $326.74
Low: $233.12
High: $340.88

Volume

183 shs

Average Volume

4,886 shs

Market Capitalization

N/A

P/E Ratio

30.23

Dividend Yield

3.21%

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Roche?

The following Wall Street analysts have issued research reports on Roche in the last twelve months:
View the latest analyst ratings for RHHVF.

What is the current price target for Roche?

0 Wall Street analysts have set twelve-month price targets for Roche in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Roche in the next year.
View the latest price targets for RHHVF.

What is the current consensus analyst rating for Roche?

Roche currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for RHHVF.

What other companies compete with Roche?

Other companies that are similar to Roche include (BVII), 30DC, Aalberts, Absa Group and Air China. Learn More about companies similar to Roche.

How do I contact Roche's investor relations team?

Roche's physical mailing address is Grenzacherstrasse 124, Basel, Basel-Stadt (Basle. The company's listed phone number is (161) 688-1111. The official website for Roche is www.roche.com. Learn More about contacing Roche investor relations.